![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
PA Vasey, NA Jones, S Jenkins, C Dive and R Brown
Cancer Research Campaign Department of Medical Oncology, Beatson Laboratories, Glasgow, UK.
With the use of clonogenic survival assays, we show that wild-type p53- expressing A2780 human ovarian cell lines transfected with a dominant negative mutant p53 gene (codon 143, valine to alanine) acquired cross- resistance to ionizing radiation, cisplatin, doxorubicin, and 1-beta-D- arabinofuranosylcytosine. However, these mutant p53-transfected cell lines retained sensitivity to taxol and camptothecin. We also show that immature thymocytes from mice with the p53 gene genetically inactivated showed reduced ability to undergo apoptosis after treatment with ionizing radiation and cisplatin compared with wild-type mice. However, taxol-induced apoptosis in thymocytes does not seem to be dependent on p53 status. Camptothecin also induced apoptosis in a p53-independent manner in thymocytes at low doses but in a p53-dependent manner at high doses. These data suggest that taxoids and camptothecin analogs could have activity in tumors that have aberrant p53 function and provide a rationale for the clinical observations of responsiveness of refractory ovarian cancer to these drugs.
This article has been cited by other articles:
|
|
 |
|
  R. P. C. Wong, W. P. Tsang, P. Y. Chau, N. N. Co, T. Y. Tsang, and T. T. Kwok p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3 Mol. Cancer Ther., March 1, 2007; 6(3): 1054 - 1061. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Lu, T.-K. Yeh, M. Tsai, J. L.-S. Au, and M. G. Wientjes Paclitaxel-Loaded Gelatin Nanoparticles for Intravesical Bladder Cancer Therapy Clin. Cancer Res., November 15, 2004; 10(22): 7677 - 7684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E.M. Vickers, K. Rose, R. Fisher, M. Saulnier, P. Sahota, and P. Bentley Kidney Slices of Human and Rat to Characterize Cisplatin-Induced Injury on Cellular Pathways and Morphology Toxicol Pathol, August 1, 2004; 32(5): 577 - 590. [Abstract] [PDF]
|
|
|
|
|
|
K. Nakayama, A. Kanzaki, K. Terada, M. Mutoh, K. Ogawa, T. Sugiyama, S. Takenoshita, K. Itoh, N. Yaegashi, K. Miyazaki, et al. Prognostic Value of the Cu-Transporting ATPase in Ovarian Carcinoma Patients Receiving Cisplatin-Based Chemotherapy Clin. Cancer Res., April 15, 2004; 10(8): 2804 - 2811. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Petit, D. J. Bearss, D. A. Troyer, R. M. Munoz, and J. J. Windle p53-independent Response to Cisplatin and Oxaliplatin in MMTV-ras Mouse Salivary Tumors Mol. Cancer Ther., February 1, 2003; 2(2): 165 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Vasey, L. N. Shulman, S. Campos, J. Davis, M. Gore, S. Johnston, D. H. Kirn, V. O'Neill, N. Siddiqui, M. V. Seiden, et al. Phase I Trial of Intraperitoneal Injection of the E1B-55-kd-Gene-Deleted Adenovirus ONYX-015 (dl1520) Given on Days 1 Through 5 Every 3 Weeks in Patients With Recurrent/Refractory Epithelial Ovarian Cancer J. Clin. Oncol., March 15, 2002; 20(6): 1562 - 1569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Reles, W. H. Wen, A. Schmider, C. Gee, I. B. Runnebaum, U. Kilian, L. A. Jones, A. El-Naggar, C. Minguillon, I. Schonborn, et al. Correlation of p53 Mutations with Resistance to Platinum-based Chemotherapy and Shortened Survival in Ovarian Cancer Clin. Cancer Res., October 1, 2001; 7(10): 2984 - 2997. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. C. T. van Oijen and P. J. Slootweg Gain-of-Function Mutations in the Tumor Suppressor Gene p53 Clin. Cancer Res., June 1, 2000; 6(6): 2138 - 2145. [Abstract] [Full Text]
|
|
|
|
|
|
G. Aquilina, S. Ceccotti, S. Martinelli, S. Soddu, M. Crescenzi, P. Branch, P. Karran, and M. Bignami Mismatch Repair and p53 Independently Affect Sensitivity to N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea Clin. Cancer Res., February 1, 2000; 6(2): 671 - 680. [Abstract] [Full Text]
|
|
|
|
|
|
E. Harper, W. Dang, R. G. Lapidus, and R. I. Garver Jr. Enhanced Efficacy of a Novel Controlled Release Paclitaxel Formulation (PACLIMER Delivery System) for Local-Regional Therapy of Lung Cancer Tumor Nodules in Mice Clin. Cancer Res., December 1, 1999; 5(12): 4242 - 4248. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Tseng, M. S. Bobola, M. S. Berger, and J. R. Silber Characterization of paclitaxel (Taxol(R)) sensitivity in human glioma- and medulloblastoma-derived cell lines Neuro-oncol, April 1, 1999; 1(2): 101 - 108. [Abstract] [PDF]
|
|
|
|
 |
|
 N. A. Jones, J. Turner, A. J. McIlwrath, R. Brown, and C. Dive Cisplatin- and Paclitaxel-Induced Apoptosis of Ovarian Carcinoma Cells and the Relationship between Bax and Bak Up-Regulation and the Functional Status of p53 Mol. Pharmacol., May 1, 1998; 53(5): 819 - 826. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. S. Duckett, F. Li, Y. Wang, K. J. Tomaselli, C. B. Thompson, and R. C. Armstrong Human IAP-Like Protein Regulates Programmed Cell Death Downstream of Bcl-xL and Cytochrome c Mol. Cell. Biol., January 1, 1998; 18(1): 608 - 615. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. Briasoulis and N. Pavlidis Cancer of Unknown Primary Origin Oncologist, June 1, 1997; 2(3): 142 - 152. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
